Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Dimed Distribuidora de MedicamentosBSP:PNVL3 +1.43%89 Return-on-Tangible-Equity is 11.24% as of Mar. 2026, which is 11% above its 10-year median of 10.13. GuruFocus rates BSP:PNVL3 with a GF Score™ of 89/100 and a GF Value™ of R$13.65 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 901 Drug Manufacturers companies, Dimed Distribuidora de Medicamentos ranks better than 60.6% on this metric.
The historical rank and industry rank for Dimed Distribuidora de Medicamentos's Return-on-Tangible-Equity or its related term are showing as below:
BSP:PNVL3'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 7.71 Med: 10.13 Max: 17.75
Current: 11.41
During the past 13 years, Dimed Distribuidora de Medicamentos's highest Return-on-Tangible-Equity was 17.75%. The lowest was 7.71%. And the median was 10.13%.
BSP:PNVL3's Return-on-Tangible-Equity is ranked better than 60.6% of 901
companies
in the Drug Manufacturers industry
Industry Median: 7.9
vs BSP:PNVL3: 11.41
Dimed Distribuidora de Medicamentos (BSP:PNVL3) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Dimed Distribuidora de Medicamentos Return-on-Tangible-Equity Related Terms
Dimed Distribuidora de Medicamentos Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dimed Distribuidora de Medicamentos Return-on-Tangible-Equity Chart
BSP:PNVL3 vs LLY, JNJ, ABBV: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - General subindustry, Dimed Distribuidora de Medicamentos's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dimed Distribuidora de Medicamentos Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Dimed Distribuidora de Medicamentos's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Dimed Distribuidora de Medicamentos's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 11.24% mean?
Dimed Distribuidora de Medicamentos (BSP:PNVL3) has a Return-on-Tangible-Equity of 11.24% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Dimed Distribuidora de Medicamentos and its competitors. This is 11% above median its historical median of 10.13. Over the past decade, Dimed Distribuidora de Medicamentos' Return-on-Tangible-Equity has ranged from 7.71 to 17.75. According to the industry distribution chart, Dimed Distribuidora de Medicamentos ranks #355 out of 901 companies in the Drug Manufacturers industry, placing it in the top 39.4%.
Is Dimed Distribuidora de Medicamentos' Return-on-Tangible-Equity too high?
Dimed Distribuidora de Medicamentos' current Return-on-Tangible-Equity of 11.24% is 11% above median its 10-year median of 10.13. Over the past 10 years, this metric has ranged from a low of 7.71 to a high of 17.75. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.90. Dimed Distribuidora de Medicamentos' value of 11.24% is 42.3% above this industry median. Based on the distribution chart, Dimed Distribuidora de Medicamentos ranks #355 out of 901 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Dimed Distribuidora de Medicamentos has a GF Score™ of 89/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Dimed Distribuidora de Medicamentos' Return-on-Tangible-Equity compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Dimed Distribuidora de Medicamentos ranks #355 out of 901 companies for Return-on-Tangible-Equity. This puts Dimed Distribuidora de Medicamentos in the upper half of its industry. The industry median Return-on-Tangible-Equity is 7.90. Dimed Distribuidora de Medicamentos' value of 11.24% is 42.3% above this benchmark. Historically, Dimed Distribuidora de Medicamentos' own Return-on-Tangible-Equity has ranged from 7.71 to 17.75 over the past decade. While the company's 10-year median is 10.13 vs. the industry median of 7.90, Dimed Distribuidora de Medicamentos has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.90, based on 901 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dimed Distribuidora de Medicamentos's current Return-on-Tangible-Equity of 11.24% is 42.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Dimed Distribuidora de Medicamentos and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dimed Distribuidora de Medicamentos's current Return-on-Tangible-Equity is 11.24%, which is 11% above median its own 10-year median of 10.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dimed Distribuidora de Medicamentos stock overvalued right now?
Based on GuruFocus' analysis, Dimed Distribuidora de Medicamentos (BSP:PNVL3) is currently considered Modestly Undervalued. The stock's GF Value™ is R$13.65, compared to a current price of R$11.33 — trading 17% below its estimated fair value. The current Return-on-Tangible-Equity is 11.24%, which is 11% above median its 10-year median of 10.13 and 42.3% above the Drug Manufacturers industry median of 7.90. Dimed Distribuidora de Medicamentos' overall GF Score™ is 89/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Dimed Distribuidora de Medicamentos (BSP:PNVL3), the current Return-on-Tangible-Equity is 11.24% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dimed Distribuidora de Medicamentos (BSP:PNVL3) Overvalued in 2026?
Based on GuruFocus' analysis, Dimed Distribuidora de Medicamentos stock appears to be undervalued.
The current stock price of R$11.33 is trading 17% below its estimated GF Value™ of R$13.65.
GuruFocus considers Dimed Distribuidora de Medicamentos to be Modestly Undervalued.
Key valuation signals for BSP:PNVL3:
Return-on-Tangible-Equity: 11.24% (11% above median its 10-year median of 10.13)
GF Value™: R$13.65 vs. price of R$11.33 (17% below fair value)
Industry Position: 42.3% above the Drug Manufacturers median (#355 of 901)
No single metric tells the full story. See the BSP:PNVL3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dimed Distribuidora de Medicamentos Business Description
Dimed SA Distribuidora de Medicamentos is engaged in the sale of medicines, perfumery, personal care and beauty products, cosmetics and dermocosmetics. It has single reportable segment that is, The Retail segment. The Retail segment has 556 stores that sell more than 15,000 items among drugs and personal care and beauty products. In addition to adding divisions of cosmetics, drugs and food, Lifar is responsible for the production of brands in Brazil, as well as products of its own brand Panvel.
89GF Score
Get the complete analysis for BSP:PNVL3
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:PNVL3 has been successfully added to your 
